August 20, 2024, New Richmond, WI
Oculogica Inc. is pleased to highlight a publication this week by a Department of
Defense based research team on the company’s EyeBOX concussion diagnostic
technology. The study, Comparative Performance of Three Eye-Tracking Devices in
Detection of Mild Traumatic Brain Injury in Acute Versus Chronic Subject Populations,
was published in Military Medicine on August 17, 2024. The study was led by Dr. John
King of the Center for Military Psychology and Neuroscience, Walter Reed Army
Institute of Research (WRAIR), Silver Spring, MD. The study team also included Ms.
Chantele Friend, of the Henry M. Jackson Foundation for the Advancement of Military
Medicine, Dr. Dong Zhang of Bloomberg University, and Major Walter Carr, also of
WRAIR.
The research included 216 participants ages 18-45 in 3 groups: those with a recent
concussion within 72 hours of injury, those with a concussion sustained several months
or more ago, and a group with no history of concussion. Participants underwent tests
with all three eye-tracking based concussion diagnostics – NeuroSync’s EYE-SYNC,
Oculogica’s EyeBOX and NeuroKinetics’ IPAS devices, in random order to prevent bias
due to fatigue.
The study compared the performance and usability of the three eye-tracking devices
with each other and a clinical reference standard for concussion, also referred to as mild
traumatic brain injury (mTBI). Measures from Oculogica’s EyeBOX demonstrated the
highest diagnostic sensitivity for those with recent concussion and the highest specificity
for those with a concussion sustained a month or more ago. The EyeBOX also had the
lowest rate of poor-quality scans, was rated easiest to use, and cited as the only device
that does not require calibration.
“Using eye-tracking technology is a needed step in the right direction for concussion
diagnosis. Having an objective way to better understand what is going on with a
patient’s brain is critical to getting patients better, more quickly. We’re thrilled with the
outcome of this study, validating the quality of our technology by a completely
independent research group,” said Oculogica CEO Rosina Samadani, Ph.D.
The EyeBOX technology is the first non-invasive concussion diagnostic approved by the
FDA for aid in the diagnosis of concussion that does not require a pre-injury baseline
test. Leading clinics, such as the Mayo Clinic, Midwest Orthopedics at Rush University
and Minneapolis Clinic of Neurology, amongst others, offer the technology.
The full publication by Dr. King and his colleagues, and other publications on
Oculogica’s EyeBOX technology, are available here: https://oculogica.com/publications/.